Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | JAK3 Q988P |
| Therapy | LGH447 |
| Indication/Tumor Type | hematologic cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK3 Q988P | hematologic cancer | sensitive | LGH447 | Preclinical - Cell culture | Actionable | In a preclinical study, LGH447 inhibited viability and proliferation of transformed cells expressing JAK3 Q988P in culture (PMID: 39033228). | 39033228 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39033228) | PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL. | Full reference... |